FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/30/2024
Back to search
Official data from USPTO
CHIRAL CQ QUEST
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
11/30/2024
Trademark type
Combined
Nice classes
1, 5, 40
Filing date
09/02/2022
Registration date
05/28/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/28/2024
Last transaction
05/28/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
CN
Examiner
RIEPEL, CHRISTINA
Law office
N60
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the capitalized words "CHIRAL QUEST" with a diamond-shaded figured formed by the letters "C" and "Q" at the center. The left part of the figure is a solid black line, and the right part of the figure is a black and white stripe.
Holders and representatives
Holders
Chiral Quest (Suzhou) Co., Ltd.
Representatives
Richard A. Arrett Vidas, Arrett & Steinkraus, P.A.
Technical classification
Nice Classes
Class 1Class 5Class 40
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Hydrochlorates; benzene derivatives being industrial chemicals; p-aminophenol; agricultural chemicalsexcept fungicidesherbicidesinsecticides and parasiticides; chemical substances for analyses in laboratoriesother than for medical or veterinary purposes; catalysts for oxidation process; biochemical catalysts; chemical preparations for scientific purposesother than for medical or veterinary use; chemical preparations for analyses in laboratoriesother than for medical or veterinary purposes; catalysts for chemical and biochemical processes
Class 5
Medicines for human purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; pharmaceutical preparations for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; chemico-pharmaceutical preparations for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; drugs for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; biological preparations for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; amino acids for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; active pharmaceutical ingredientnamely amino acids derivativeschiral or heterocyclic molecular derivatives for medical purposes; chemical reagents for medical or veterinary purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; chemical preparations for medical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology; chemical preparations for pharmaceutical purposes for treatment of vascular diseasesdiabetes and infectious diseasesfor use in the treatment of diseases and disorders in the fields of oncologycardiologyimmunologyneurology
Class 40
Recycling of chemicals; water treating; cryopreservation services; medicinal materials processingnamely processing of amino acids derivativeschiral or heterocyclic molecular derivatives; chemical processing
Publications
History of USPTO decisions and trademark events.
39 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/10/2024
FIMP
FINAL DISPOSITION PROCESSED
11/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/28/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/28/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/21/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/01/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/01/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/12/2024
PUBO
PUBLISHED FOR OPPOSITION
03/12/2024
GPNX
NOTIFICATION PROCESSED BY IB
03/11/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/21/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/21/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/21/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/21/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/30/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
01/30/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/30/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
01/30/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/30/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/29/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/29/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/29/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/29/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
01/29/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/29/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/29/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/29/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/29/2024
RFNT
REFUSAL PROCESSED BY IB
08/21/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/03/2023
RFRR
REFUSAL PROCESSED BY MPU
08/03/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/27/2023
CNRT
NON-FINAL ACTION WRITTEN
06/26/2023
DOCK
ASSIGNED TO EXAMINER
06/20/2023
MAFR
APPLICATION FILING RECEIPT MAILED
12/06/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/01/2022
Continuous trademark protection
Get notified about every new filing that threatens CHIRAL CQ QUEST or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.